Fundraising FoxPfizer Ventures — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)inKevin Pojasekin
Co-investorsRA CapitalSamsara BioCapitalSV Health InvestorsDementia Discovery FundM VenturesPfizer Venture Investments
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in
Co-investorsAndera PartnersCanaan PartnersOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalEarlybird Venture Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.